Freeline Therapeutics Holdings plc Gross Profit

Freeline Therapeutics Holdings plc (FRLN) currently reports a gross profit of $-840K as of September 2023. That compares with $-400K in the prior-year period — down 107.8% year over year. That is below the Healthcare sector average of $66B. Use the charts on this page to explore Freeline Therapeutics Holdings plc's gross profit history and peer comparisons.

Freeline Therapeutics Holdings plc's gross profit decreased from $-400K to $-840K — a 107.8% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Freeline Therapeutics Holdings plc's gross profit of $-840K is lower than the Healthcare sector average of $66B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Freeline Therapeutics Holdings plc reported $-840K in gross profit as of September 2023. That compares with $-400K in the prior-year period — down 107.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $-840K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $66B. From there, open related valuation or income-statement pages for Freeline Therapeutics Holdings plc, and consider following FRLN for alerts when major investors trade the stock.